anakinra
Selected indexed studies
- Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review. (Eur J Haematol, 2023) [PMID:37344166]
- Anakinra in children and adults with Still's disease. (Rheumatology (Oxford), 2019) [PMID:31769856]
- Anakinra-Associated Amyloidosis. (JAMA Dermatol, 2022) [PMID:36223107]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review. (2023) pubmed
- Anakinra in children and adults with Still's disease. (2019) pubmed
- Anakinra-Associated Amyloidosis. (2022) pubmed
- Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis. (2023) pubmed
- Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. (2020) pubmed
- Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. (2021) pubmed
- Anakinra in Recurrent Pericarditis: Current Evidence on Clinical Use, Effectiveness, and Safety. (2020) pubmed
- Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. (2018) pubmed
- Anakinra for rheumatoid arthritis. (2009) pubmed
- Anakinra in Sanfilippo syndrome: a phase 1/2 trial. (2024) pubmed